Johnson & Johnson’s Animas subsidiary is getting out of the insulin-pump business, leaving 90,000 people with diabetes with questions about their future.
Johnson & Johnson’s Animas subsidiary is getting out of the insulin-pump business, leaving 90,000 people with diabetes with questions about their future. Associated Press
Johnson & Johnson’s Animas subsidiary is getting out of the insulin-pump business, leaving 90,000 people with diabetes with questions about their future. Associated Press